Prenessa

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prenessa

Prenessa is a medicinal product whose active substance is perindopril (specifically, perindopril tert-butylamine). It belongs to a class of medications called Angiotensin-Converting Enzyme (ACE) inhibitors.

Mechanism of Action

Perindopril is a prodrug, meaning it is converted in the body—specifically in the liver—to its active form, perindoprilat. Perindoprilat works by inhibiting the ACE enzyme, which is responsible for converting Angiotensin I to the potent vasoconstrictor, Angiotensin II. By blocking this conversion, Prenessa helps to relax and widen blood vessels (vasodilation) and reduces the amount of fluid retained by the body. This combined action lowers blood pressure and decreases the workload on the heart.

Therapeutic Use

Perindopril is typically prescribed to treat:

  • High Blood Pressure (Hypertension): Used alone or with other medications to lower blood pressure, which helps reduce the risk of complications such as stroke and heart attack.
  • Stable Coronary Artery Disease (CAD): Used to reduce the risk of cardiovascular events, such as a heart attack, in patients who have stable CAD.

What side effects are possible with Prenessa?

Possible side effects and safety information

The safety profile of Prenessa (perindopril) is documented in official regulatory sources, with adverse reactions formally categorized by frequency and the body system affected.

Frequency and System-Organ Classifications

Adverse reactions are classified according to incidence observed in clinical trials, including the following common effects (occurring in 1% or more of patients):

Classification Examples of Officially Listed Reactions
Common Cough (often persistent), Dizziness, Headache, Back pain, Diarrhea, Abdominal pain.
Uncommon Syncope (fainting), Somnolence (drowsiness), Paresthesia, Dry mouth.

Serious Adverse Reactions and Safety Constraints

A potential serious adverse reaction is Angioedema, which involves rapid swelling of the face, extremities, lips, tongue, or airway. Airway involvement may be fatal. Other serious events documented in regulatory labeling include Severe Symptomatic Hypotension (low blood pressure), Acute Renal Failure, and Hepatic Failure.

Safety notes specify that symptomatic hypotension is most likely to occur at the initiation of therapy and following dose increases. The risk of angioedema is noted to be higher in African-American patients receiving this class of medication.

Population-Specific Safety

Pregnancy is a safety constraint. Use of perindopril during the second and third trimesters is officially documented to cause injury or death to the developing fetus. The medicine is also not recommended for use in patients with severe renal impairment (creatinine clearance below 30 mL/min). Official labeling restricts concomitant use with medications such as aliskiren in patients with diabetes, or with sacubitril/valsartan, due to documented safety concerns.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Prenessa (perindopril) requires immediate medical attention and is managed by specialized supportive care, as documented in official regulatory information.

Documented Overdose Manifestations

The most commonly reported effect of a perindopril overdose is marked hypotension (severe low blood pressure), which may be accompanied by dizziness or lightheadedness. Other serious manifestations recorded in official labeling include:

  • Cardiovascular: Circulatory shock, tachycardia (rapid heart rate), palpitations, and bradycardia (slow heart rate).
  • Systemic/Organ: Electrolyte disturbances and acute renal failure.
  • Other: Hyperventilation, anxiety, and cough.

Required Emergency Actions

Official regulatory sources define the necessary professional actions for managing an overdose, emphasizing symptomatic and supportive treatment:

  1. Seek Urgent Medical Help: Immediate transport to an emergency facility is necessary for close monitoring and treatment of vital functions.
  2. Initial Stabilization: The patient should be placed in a supine position (lying down).
  3. Volume Replacement: If marked hypotension persists, intravenous administration of physiological saline or other volume expanders is required.
  4. Advanced Treatment: Intravenous catecholamines may be administered if volume replacement is insufficient.
  5. Elimination: The active metabolite of Prenessa, perindoprilat, is dialysable (can be removed from the blood by haemodialysis).

Therapeutic Uses of Prenessa

What Prenessa Treats: Main Uses and Benefits

Prenessa (perindopril) is a medication commonly used in the long-term management of chronic cardiovascular conditions to support stability. Its primary role is to help manage chronic disease and assist with reducing the risk of major cardiovascular events.

The therapeutic use is generally relevant across key domains, including the management of elevated systemic arterial pressure (Hypertension), contributes to cardiovascular support for those with Stable Coronary Artery Disease, and offers support for patients with Chronic Heart Failure. This supportive treatment may assist with reducing the risk of serious future events, such as stroke and heart attack, which helps in managing the systemic burden associated with the condition. The medication plays a role in managing symptoms related to fluid retention and supports the patient by easing distress.

“This medication is primarily relevant in contexts marked by increased systemic burden, and is used to provide symptomatic relief to help manage major cardiovascular risks.”

Quick Fact: Relief for Elevated Systemic Pressure The medication is relevant for easing conditions presenting with elevated systemic arterial pressure, and its use may assist with maintaining functional stability for patients during symptomatic phases of chronic disease.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Contraindications and Eligibility Restrictions

Prenessa (perindopril) is an ACE inhibitor for which official regulatory documents establish specific populations who must not use the medicine.

Absolute Contraindications

Category Prohibited Populations
Allergy/History Patients with known hypersensitivity to perindopril, any other ACE inhibitor, or a history of angioedema related to previous ACE inhibitor use, or hereditary/idiopathic angioedema.
Pregnancy Status Women in the second or third trimesters of pregnancy. Use is not recommended in the first trimester; treatment should be stopped immediately upon detection of pregnancy.
Concomitant Use Patients taking sacubitril/valsartan (a 36-hour washout period is required when switching) or aliskiren if they have diabetes mellitus or certain levels of renal impairment.
Medical Procedures Patients undergoing specific extracorporeal treatments (e.g., certain dialysis/hemofiltration procedures).

Populations with Restricted Use

The medicine is not recommended for children and adolescents under 18 years of age, as safety and efficacy have not been established. Use in breastfeeding mothers is also not recommended. Patients with severe hepatic or severe renal impairment should only use the medicine with extreme caution, and the initial dose may require specific adjustment based on regulatory guidance. Older adults may also require closer monitoring of renal function during initial treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Perindopril (Prenessa) has officially documented interaction patterns primarily focused on pharmacodynamic (PD) effects and the Renin-Angiotensin System (RAS), as described in regulatory labels. These interactions result in specific prohibitions and restrictions.

Contraindicated Combinations

Co-administration with sacubitril/valsartan is formally contraindicated due to the significantly increased risk of angioedema. A mandatory 36-hour separation period is required when switching between these agents. Co-administration with aliskiren-containing products is also contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment.

Key Pharmacodynamic and Exposure Interactions

  • Agents that increase serum potassium: The combination with potassium-sparing diuretics (e.g., spironolactone) and potassium supplements is generally not recommended due to the additive risk of hyperkalemia (increased potassium levels).
  • Lithium: Concomitant use may lead to increased serum lithium concentrations and toxicity.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Use may result in a loss of antihypertensive effect and an increased risk of renal function deterioration.
  • Population Exposure: Clearance of the active metabolite, perindoprilat, is reduced in elderly patients and those with renal impairment, increasing the potential for interactions.
  • Timing: To reduce the risk of symptomatic hypotension, the use of non-potassium sparing diuretics may require discontinuation 2 to 3 days prior to perindopril initiation.

Mechanism of Action

Prenessa (perindopril) is administered as a prodrug that is hepatically metabolized into its active form, perindoprilat. Perindoprilat functions as a competitive, specific inhibitor of the angiotensin-converting enzyme (ACE), a dipeptidyl carboxypeptidase primarily located on the vascular endothelium. Inhibition of ACE prevents the conversion of the inactive decapeptide angiotensin I into the potent octapeptide angiotensin II. This action effectively disrupts the primary vasoconstrictive and trophic signaling cascade of the renin-angiotensin-aldosterone system (RAAS). The resultant decrease in systemic Angiotensin II concentration leads to peripheral vasodilation due to reduced arteriolar resistance, and decreased aldosterone secretion from the adrenal cortex, which subsequently lowers renal sodium and water retention. Furthermore, the reduction in Angiotensin II's trophic signaling modulates vascular smooth muscle remodeling and minimizes myocardial hypertrophy.

Dosage and Administration Information

How to Use Prenessa (Perindopril)

Perindopril is administered orally and is typically prescribed for long-term management of chronic cardiovascular conditions. This includes specific patterns for initiation, maintenance, and necessary dose adjustments.


Administration Requirements

Feature Instruction Summary
Timing and Frequency Taken once daily in the morning.
Food Relationship Administration must occur before a meal (e.g., breakfast) as food may decrease absorption.
Dose Titration Dosing starts low and is gradually increased (titrated) over several weeks (e.g., every two to four weeks) based on the prescribed regimen.
Missed Dose If a dose is missed, skip the missed dose and take the next dose at the regular scheduled time. Do not double the dose.

Standard Dosing and Adjustment Rules

The standard regimen specifies distinct starting and maintenance doses for each approved use.

Indication Typical Starting Dose Maintenance Dose Range (Maximum)
Hypertension 4 mg once daily 4 mg to 8 mg daily (16 mg maximum)
Stable Coronary Artery Disease 4 mg once daily for two weeks 8 mg once daily

Population-Specific Dosing: Adjustments are required for certain patient groups. Older adults (e.g., age 70 years) generally require a lower initial dose and a slower titration schedule. For patients with impaired kidney function, the dose must be adjusted based on the individual's Creatinine Clearance measurement. Use in pediatric patients (<18 years) is not recommended. Additionally, if the patient is taking a diuretic, a temporary reduction or withdrawal of the diuretic may be advised before initiating perindopril.

Recent Clinical Evidence

Prenessa, which contains the active substance perindopril, an Angiotensin-Converting Enzyme (ACE) inhibitor, has been the subject of several large-scale clinical trials that have established its efficacy not only for controlling high blood pressure (hypertension) but also for reducing the risk of cardiovascular events.

Cardiovascular and Cerebrovascular Risk Reduction

Major randomized controlled trials have demonstrated that perindopril-based therapy significantly reduces the risk of cardiovascular morbidity and mortality across various patient populations. Key findings include:

  • Stable Coronary Artery Disease: Studies show that perindopril, when added to standard treatment (such as antiplatelet agents and statins), is associated with a lower risk of cardiovascular death, non-fatal myocardial infarction (heart attack), and cardiac arrest.
  • Stroke Prevention: In patients with a history of stroke or transient ischemic attack (TIA), a regimen including perindopril, particularly when combined with a diuretic like indapamide, has been shown to reduce the risk of recurrent stroke.

Efficacy in Combination Therapy

Recent clinical evidence has increasingly focused on the benefits of fixed-dose combinations (FDCs) containing perindopril. These single-pill combinations often include a calcium channel blocker (like amlodipine) and/or a diuretic (like indapamide). Research consistently shows that these FDCs lead to superior blood pressure control compared to monotherapy, which can enhance patient adherence due to a simplified dosing regimen. Furthermore, the combination of perindopril and amlodipine has been associated with a lower incidence of peripheral edema, a common side effect of calcium channel blockers alone.

Frequently Asked Questions (FAQ)

Common questions about Prenessa (FAQ)


Q: How long does it take for Prenessa to start working?

Perindopril is rapidly absorbed into the body after it is taken. The active form of the medicine, perindoprilat, typically reaches its peak concentration in the blood between 3 to 7 hours after administration. This marks the beginning of the medicine’s action in lowering blood pressure.


Q: When can I expect to notice the full effect of Prenessa?

The active medicine in Prenessa accumulates in the bloodstream over time with repeated, daily dosing. According to official information, the concentration of the medicine generally becomes stable (known as reaching steady state) within 3 to 6 days. Regulatory documents indicate that the full therapeutic effect of the medicine on blood pressure may take several weeks to be observed.


Q: Why do people use Prenessa for heart failure in addition to high blood pressure?

Official prescribing information indicates that Prenessa is used to treat symptomatic heart failure, where it helps reduce the heart's workload. Clinical studies have shown that perindopril-based therapy is associated with a reduction in the risk of cardiovascular events, such as a heart attack, in patients who have established stable coronary artery disease.


Q: How is the cough side effect from Prenessa managed?

The cough that can occur with Prenessa is usually described as dry and non-productive. Since this type of cough is related to the way the medicine works, standard cough medicines may not be effective. If the cough is persistent or troublesome, clinical practice indicates that a change in treatment may be necessary.


Q: What are the long-term effects of taking Prenessa?

Prenessa is an ACE inhibitor approved for the long-term management of chronic conditions. While common side effects include cough and dizziness, rare, serious long-term risks, such as acute liver injury, have been reported for the ACE inhibitor class and are part of the documented safety profile.


Q: Can Prenessa cause dizziness or lightheadedness when first starting it?

Yes, dizziness and lightheadedness are common side effects that can happen as your body adjusts to the medication. These symptoms are most likely to occur when you first start taking Prenessa or if the dosage is increased, due to the medicine starting to lower blood pressure.


Q: Does Prenessa affect kidney function or require blood monitoring?

Perindopril can impact kidney function and may cause increases in blood chemicals like urea and creatinine, especially in patients with existing renal issues. Routine medical follow-up typically involves monitoring of creatinine and potassium levels to detect any potential changes, particularly in patients with existing renal concerns.


Q: Can a person with diabetes use Prenessa?

Perindopril is generally compatible with the management of diabetes. However, official information notes that the medicine can potentially lower blood sugar levels. Because of this, closer monitoring of blood sugar may be necessary, particularly during the initial phase of treatment.


Q: Why does Prenessa sometimes cause fatigue or weakness?

Fatigue and weakness have been reported as common adverse effects in clinical trials for this medicine. In some instances, these feelings may be linked to a fall in blood pressure, known as hypotension, a risk most common when treatment is first started.


Q: Can Prenessa cause a skin rash or itching?

Yes, a skin rash has been listed as a common side effect of perindopril. Swelling, a severe rash, or persistent itching are noted safety concerns that can be signs of a serious allergic reaction, such as angioedema.


Q: Does alcohol consumption interact with Prenessa?

Official information indicates that alcohol may increase the effect of Prenessa in lowering blood pressure. This additive effect may increase the risk of side effects such as dizziness or fainting, particularly during the initial phase of treatment.


Q: Are there any cold and flu medications that should be avoided with Prenessa?

Regulatory documents indicate that cold and flu medications containing sympathomimetic agents (e.g., decongestants) may cause adverse cardiovascular effects and could potentially counteract the blood-pressure lowering effect of Prenessa. These agents should be reviewed with a health professional before use.


Q: Can Prenessa interact with natural supplements or herbal products?

Interactions with herbal products are possible and should be considered. Studies have examined potential interactions between perindopril and certain supplements like Garlic. It is important to disclose all supplements or herbal products used to the prescriber due to potential interactions.


Q: What is the connection between Prenessa and the sense of taste?

Loss of taste, or a change resulting in a metallic taste in the mouth, has been reported as a side effect of perindopril in consumer information sheets. If taste changes are experienced, this is a symptom that can be addressed as part of a medical review.


Q: Can Prenessa be taken before a major surgery?

Official product information notes that perindopril can cause low blood pressure (hypotension) during major surgery and when general anesthesia is used. The prescribing physician or surgeon may decide that temporary discontinuation is necessary prior to the operation.


Q: Does general anesthesia interact with Prenessa?

Yes, regulatory documents indicate that ACE inhibitors like perindopril can lead to severe low blood pressure (hypotension) when combined with general anesthesia. For this reason, a temporary discontinuation of the medicine may be necessary before a medical procedure.


Q: Can getting sick with vomiting or diarrhea affect how Prenessa works?

Severe diarrhea or vomiting can cause significant fluid loss in the body. This volume depletion increases the risk of symptomatic low blood pressure (hypotension) when taking Prenessa. In such cases, the treatment may require temporary adjustment until the patient recovers from the illness.


Q: Is it true that high salt intake can reduce the effect of Prenessa?

Clinical practice notes that while low salt intake can increase the risk of low blood pressure when starting Prenessa, a high salt intake can potentially reduce the medicine's effectiveness in lowering blood pressure. Consistency in dietary intake is a factor that supports stable management of the condition.


Q: Can Prenessa cause sun sensitivity or make a person sunburn more easily?

According to consumer safety information, this medication may make you more sensitive to the sun. Measures such as limiting sun exposure, avoiding tanning beds, and using sun protection are commonly advised for patients using this medicine.


Q: Can Prenessa affect a patient's blood sugar levels?

Official safety information indicates that perindopril can potentially lower blood sugar levels in people with diabetes. If you have diabetes, closer monitoring of blood sugar may be necessary, particularly during the initial phase of treatment with this medicine.


Q: What are the signs of low blood pressure that may occur with Prenessa?

Low blood pressure (hypotension) can occur, especially when starting Prenessa or increasing the dose. Signs that may be experienced include dizziness, lightheadedness, or fainting, particularly if these symptoms occur when standing up quickly.


Q: Can Prenessa cause joint or muscle pain?

Back pain is listed as a common side effect of Prenessa in regulatory documents. Furthermore, muscle cramps have been reported as a possible symptom of an electrolyte imbalance, such as high potassium, which can occur due to the medicine's mechanism of action.


Q: Does Prenessa affect my cholesterol levels?

Prenessa is not classified as a cholesterol-lowering medicine. However, it is often studied and prescribed in combination with cholesterol-lowering drugs (statins) as a fixed-dose combination to treat patients who have high cardiovascular risk.


Q: Can taking Prenessa cause blurred vision?

Blurred vision is listed in official consumer and regulatory documents as a potential side effect of perindopril. Like other effects such as dizziness, this may be more noticeable when starting the medication.


Q: Is a metallic taste a known side effect of this class of medication?

Yes, a metallic taste in the mouth has been reported as a side effect associated with the use of perindopril. This is noted in patient information leaflets derived from the safety data.


Q: Is it safe to take common over-the-counter antacids with Prenessa?

While not a formal contraindication, studies indicate that antacids may potentially decrease how well the body absorbs some ACE inhibitors. Patients are commonly advised to consider separating the administration of Prenessa and any antacids by at least one to two hours to avoid this effect.


Q: Is it normal for Prenessa to cause no immediate physical change?

Yes, it is common for many people not to feel any immediate or significant difference when taking this type of medication. Prenessa works over time to achieve a stable lowering of blood pressure, and this therapeutic effect often occurs without noticeable physical symptoms.

How should Prenessa be stored and disposed of?

Official Storage and Disposal Requirements

Storage Requirement Official Classification/Statement
Temperature Store below 25 C or 30 C (Room Temperature), as specified on the authorized label.
Protection Store in the original package to protect from light and moisture; keep the container tightly closed.
Child Safety Keep this medicine out of the sight and reach of children.

Regulatory documents define the storage profile by setting a maximum storage temperature and mandating that the tablets remain in their original packaging to guard against environmental factors like moisture and light. This protection is necessary to maintain the product's integrity and full stability period.

Disposal Instructions

Any unused or expired Prenessa should be disposed of in accordance with local requirements. The best methods include utilizing a community drug take-back program or a mail-back envelope. The medication must not be disposed of via wastewater (i.e., flushed down the toilet or poured down the sink) or placed in household trash unless first mixed with an undesirable substance like dirt or coffee grounds and sealed, to prevent environmental contamination and misuse.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prenessa found in:

A-Z Index: